Objective To assess parental attitudes regarding placebo use in pediatric randomized controlled trials and clinical care.
P lacebos have been crucial for the evaluation of new therapies in clinical trials 1 and are an important therapeutic tool in clinical practice globally. [2] [3] [4] [5] [6] [7] [8] However, the use of placebos in clinical trials and practice poses ethical and scientific challenges, especially with children, who cannot exercise the principle of autonomy and are subject to parental decision making on their behalf. 9, 10 Importantly, more than one-half of the pharmacologic agents used in pediatric care rely on evidence generated from adult populations that sometimes differ significantly in terms of safety and efficacy profiles when studied in the pediatric population. [11] [12] [13] [14] [15] On the other hand, placebo responses seem to be more marked in children than in adults, [16] [17] [18] [19] [20] emphasizing the relevance of this effect in the pediatric field and the importance of parental consent decisions.
Recent adult [21] [22] [23] and pediatric 24 trials have shown that clinically relevant placebo responses can be obtained in a nondeceptive, transparent manner (ie, open-label placebo). In line with this idea, survey findings consistently suggest that adult patients are open to placebo use, but that their attitudes depend on several factors, such as the purpose of treatment and transparency. [25] [26] [27] [28] Children require special considerations, however. 9, 10, 29 The literature regarding parental attitudes toward their child's participation in clinical trials highlights a number of specific concerns, most notably treatment safety, but also the inconvenience of the research process and a greater need for clarity in the information provided. [30] [31] [32] [33] [34] [35] Because safety is a major concern, placebos (usually assumed to be ineffective) may be perceived as an unacceptable risk. 33, 35 Few parents seem to understand the rationale for placebo use, equating placebo with abandonment of treatment. 35 Parents' perceptions have been shown to influence the placebo effect in their children. 36 Thus, parental education might result in a preference for placebo over pharmacotherapy owing to potential placebo effectiveness and decreased use of pharmacologic agents with potential side effects. 37 Understanding how parents weigh the risks and benefits related to placebo may be central to pediatrics. Within the field of pediatric research, there is a significant need for placebo-controlled data, [11] [12] [13] [14] [15] and within the pediatric clinic, the need for parental support for noninvasive interventions and minimal risk interventions is also important. Parents are invested stakeholders in the advancement of pediatric science and clinical care.
Despite the importance of placebos in the pediatric field [2] [3] [4] [5] [6] [7] [8] and the role of parental views in this context, parents' voices have been absent in the ongoing placebo debate. In this study, we aimed to explore parents' perspectives and concerns regarding the use of placebos in pediatric research and care, after providing current information about how placebos are used in both domains. Insight into about how parents view placebo may aid the development of guidelines for physicians and enable educated parental decisions concerning the use of placebos in pediatrics.
Methods
Participants (n = 1300) living in the US were recruited with a Human Intelligence Task (HIT) posted on Mechanical Turk (MTurk), 38 an online crowdsourcing marketplace, concerning parental attitudes on placebo. We posted a link for a webbased survey administered by SurveyGizmo, an online software company, into an MTurk HIT. MTurk, run by Amazon.com, provides an online workforce that has been adopted by the research community to recruit online study participants. It was built specifically for surveys and thus finds unique workers/ participants. A growing body of evidence has validated the use of MTurk in behavioral research, and no significant differences have been found between participants recruited through MTurk and those recruited through traditional channels. [39] [40] [41] [42] [43] From the original 1300 participants, 300 were excluded owing to inconsistent information regarding their parenthood (n = 16), random responses (n = 234), or no answers (n = 50). Detailed information regarding inclusion and exclusion criteria is provided in Appendix 1 (available at www.jpeds.com). The study was approved by the Massachusetts Institute of Technology's Institutional Review Board.
The survey was developed to access parents' attitudes and perceptions regarding the use of placebo in pediatrics. The survey itself and a description of how it was organized are provided in Appendix 2 (available at www.jpeds.com). Some of the questions were adapted from a previous survey.
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Statistical Analyses
Data were analyzed using SPSS version 22.0 (IBM, Armonk, New York). The Mann-Whitney U test was used to assess whether parents' attitudes differed based on the sex (ie, mother vs father) and on whether their child was or was not hospitalized. Spearman correlations were calculated to assess associations between parental age and education with parental attitudes toward placebo. To adjust for multiple comparisons, Bonferroni correction was applied, and significance levels were set at P < .001.
Results
Data collection was performed between September and November 2014. We merged positive responses ([strongly agree, agree, and somewhat agree] or [a lot, a fair amount] or yes) vs negative responses ([somewhat disagree, disagree, and strongly disagree] or [a little, not at all] or no) for most questions. Additional analyses exploring differences in parental attitudes based on parental sex, age, and education and child's hospitalization were performed. No differences in parental attitudes were found between mothers and fathers, or between parents whose child had been hospitalized for more than 3 days and those whose child had not been hospitalized. Moreover, no associations were found between parents' education and their attitudes. Small associations were found for parental age and the following items: "If a doctor is uncertain about whether a placebo treatment will benefit my child, it is acceptable for them to recommend it to my child as long as the doctor believes it is a safe treatment" (r s = 0.12; P = .0002) and "Doctors should never recommend placebo treatments for children" (rs = −0.11; P = .0005). No other significant associations were found. Table I presents parental demographic data. Participants were fairly balanced between mothers (53.8%) and fathers (46.2%), with an average age of 35.5 ± 8.9 years. The majority of the parents had 2 children (81.1%). Although approximately onefourth (22.9%) reported that their children had been hospitalized for more than 3 days, virtually all (98.8%) considered their children to be in good health.
Parental Characteristics and Mind-Body Beliefs
When the parents were asked about their general perspective regarding mind-body therapeutic influences, most parents (83%; 95% CI, 80.6%-85.3%) reported believing that a person's mind can affect his or her heath considerably, positive thinking can improve a physical symptom of an illness significantly (71%; 95% CI, 68.1%-73.8%), and instilling hope (81.6%; 95% CI, 79.2%-84%) and involving the patient in decision making (81.5%; 95% CI, 79.1%-83.9%) are the doctor's most salient characteristics contributing to treatment outcome (Table II ; available at www.jpeds.com). Notably, only 5.6% (95% CI, 4.1%-7%) of parents reported being unfamiliar with the term "placebo." 4.7 (3.4-6.0)
If a doctor is uncertain about whether a placebo treatment will benefit my child, it is acceptable for them to recommend it to my child as long as the doctor believes it is a safe treatment.
9.4 (7. improving pediatric care, and notably, 96.5% (95% CI, 95.3%-97.6%) of parents consider the creation of guidelines for ethical and safe use of placebos in pediatrics to be imperative. If these guidelines were created, then 83.3% (95% CI, 80.9%-85.6%) of parents would be even more open toward the placebo treatment option in pediatrics (Table VI) .
Discussion
Here we report US parents' perceptions and attitudes regarding the use of placebos in pediatrics. Data indicate that the majority of the surveyed parents considered the use of placebos acceptable in pediatric care (86%) and pediatric trials (91.5%). However, their judgment and acceptance were influenced by the doctors' opinions about the therapeutic benefits of placebo treatment, the pediatric conditions for placebo use, transparency, safety, and purity of placebos. Whereas only 5.7% of parents judged the use of placebos in children to be always unacceptable, nearly all parents (96.5%) believed the creation of guidelines for ethical and safe use of placebo in pediatrics to be a critical need. Overall, the parents tended to be mostly positive and open toward the possibility of placebo treatments for their children, supporting previous positive findings regarding the use of placebos in the adult clinic. Although our data suggest that the majority of surveyed parents were positive and accepting, most parents would consent to the prescription of placebo treatment only when the targeted condition was psychological in nature or considered a "minor condition," such as a routine cold or occasional pain. These findings are consistent with previous surveys suggesting that participants believe that placebos work via psychological effects and expect psychologically vulnerable patients to respond to placebo. 25, 44 The underlying disease seems to be an important determinant in consenting to the use of placebo. 25 For the 3 infections mentioned (ie, bacterial, viral, and ear infection), placebo treatment was deemed acceptable by more than one-half of the surveyed parents only for ear infection, which might be related to the fact that ear infections are fairly common. On the other hand, the use of placebo to treat viral infections, which might underlie the common cold and for which few antiviral medicines are available, was acceptable to only 19.7% of the surveyed parents.
Underlying these choices might be insufficient information, lack of specificity or experience (eg, no treatment base for viral infections), or known lack of efficacy of so-called "known treatments." A qualitative study of irritable bowel syndrome found that a holistic approach to the etiology of symptoms resulted in greater acceptance of placebo treatment. 45 Thus, information appears to be a key factor in securing parental consent.
Regarding parental concent for clinical trials, a major obstacle to children's enrollment in randomized, placebocontrolled trials, 35 educating parents about the importance of these trials and about the central role of placebos and their safety may increase parents' willingness to allow their children to participate in these trials. In our survey, after being provided with a short description of placebos in clinical trials, more than 90% of parents considered placebo-controlled randomized clinical trials important for pediatrics, and more than twothirds reported a willingness to enroll their children in these trials. Remarkably, more than two-thirds of the surveyed parents would rather have their children enroll in a clinical trial to test the effectiveness of a new drug against a placebo as opposed to testing it against an already existing drug with possible side effects. Moreover, 81% of parents would consent to their child's enrollment in a placebo treatment even when the doctor is uncertain about its effectiveness, as long as it is safe (81%). This finding is consistent with previous studies identifying safety as a major concern for parents. 33 Therefore, reducing drug intake can be seen as a benefit. In a previous pediatric clinical trial of attention deficit hyperactivity disorder, it was reported that parents of these patients were very positive and supportive regarding a placebo dose-reduction therapy (ie, placebo was used as a complement to the stimulant medicine, reducing the doses of medicine). 24, 36 Placebo dose reduction might be an important therapeutic approach, especially when dealing with medication with significant dose-related toxicity. Thus, education on the role of placebos as controls and the potential of therapeutic benefit without pharmacologic side effects may increase trial participation. Misinformed parents may be more likely to make suboptimal decisions. Remarkably, 95% of parents would prefer to be informed about clinical trial results, and more than 67% would prefer placebo treatments to pharmacologic treatments that might not work better than placebo. These responses are consistent with previous international studies suggesting that participants are more likely to accept placebos in situations in which no effective therapies are available and in these situations, this practice is considered ethically justifiable. 25 Overall, 90% of parents recognize the importance of randomized, placebo-controlled clinical trials in pediatrics.
Consistent with previous findings, our results also emphasize the importance of transparency and honesty regarding placebo treatment in the pediatric clinic. 25, 26 Only 5.7% of parents felt it never acceptable for doctors to prescribe placebos for children. Most of the parents surveyed (52%-71.2%) judged this practice unacceptable when done deceptively; however, the majority of parents considered placebo treatment acceptable when administered honestly (81.6%), especially when pure placebos are prescribed (85.9%). Parents' opinions seem to clash with the common placebo practices adopted by physicians, which sometimes have involved deception and the use of impure placebos. 7, 8 This obvious discrepancy between parents' opinions and physicians' practices merits further attention given the negative implications for the parent-physician relationship.
Importantly, previous findings suggest that clinicians wish to take advantage of the placebo effect but do not know how to do so in a nondeceptive manner. 46 Recent studies in both pediatric and adult populations suggest that deception is not needed to achieve the desired therapeutic results with placebo. 21, 24 In fact, being transparent (to children and parents) about the administration of placebo as an adjuvant therapy for attention deficit hyperactivity disorder not only yielded equivalent THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 181 therapeutic benefits, but also led to a reduction in medication use and, consequently, fewer side effects. 24 Our survey does not make a distinction concerning transparency toward parents and transparency toward children, however. Further research regarding open placebo administration is needed, with the goal of providing specific guidelines enabling physicians to achieve the desired therapeutic effects without deceiving parents and children, thus protecting interests on both sides.
There seems to be a substantial agreement among parents (80%) that taking advantage of the placebo response may be a way to improve pediatric care. In fact, 96.5% of parents favor the creation of guidelines for the ethical and safe use of placebos in pediatrics, and 83.3% support the concept that if these guidelines existed, they would be even more open toward the placebo treatment option in pediatrics. Thus, there is a concrete need to revise some physician models and create guidelines to meet the current needs of patients and physicians alike. In pediatrics, the opportunities of using methods that can maintain therapeutic benefits while decreasing the use of medications with potential side effects and significant dose-related toxicity make successful nonpharmacologic options even more salient.
Although our study sample was diverse, it is not representative of US parents in general, being predominately Caucasian (80.2%) and also more highly educated (49% college graduates) than the general population. Our cohort was a sample of convenience. Moreover, even though we constructed our definition of placebo based on previous studies, parents may have had variable or limited understanding of the placebo concepts described, which might have influenced their responses. Social desirability also may have biased parents' responses. Furthermore, when it comes to assessing the importance of honesty and transparency in placebo administration, our survey did not make a distinction between honesty toward the parents and honesty toward the children. Finally, virtually all of the surveyed participants (98.8%) considered their children to be in good health, and their opinions might differ from those of parents faced with an actual clinical situation. 47 More empirical studies are needed, but our study points to a need to refresh traditional pediatric therapeutic models by developing guidelines and offering information regarding the potential role of placebos in pediatrics, thereby facilitating informed parental decisions. Future studies should continue investigating the therapeutic role of open-label placebo in pediatrics (eg, as adjuvant therapy), which is acknowledged by many parents as having the potential to improve general pediatric care. ■
We thank Professor Laura Schulz (Massachusetts Institute of Technology) for her help in the design of the survey and practical issues related to ethical approval and MTurk, as well as Deborah Grose for proofreading the manuscript.
Submitted for publication Feb 24, 2016 ; last revision received Aug 15, 2016; accepted Oct 5, 2016 Appendix 1
Inclusion and Exclusion Criteria
This was an "open survey" open to any MTurk users located in the US. Participation was restricted to participants with an approval rate of 95% minimum (ie, 95% of the participant's previous submissions were approved by requesters), at least 1000 HITs approved, and no duplicate submissions from the same IP address. In addition, each user received a "previous worker" tag so that he or she would not be able to take the survey again. A total of 1300 parents with children under age 18 years living in the US, as self-reported through an Amazon MTurk internet survey powered by SurveyGizmo, participated. The sample is a convenience sample of those who first responded when the survey was opened. An opening letter described the study goals (ie, to survey the attitudes of parents regarding the use of placebos in children), the time it would take to complete the survey (ie, approximately 20 minutes), and the monetary reward that was independent of their answers (ie, all received $2.00). In this introductory description, participants were also instructed to return the HIT if they did not have children under age 18 years. To ensure that the participants were honest about their parenthood, we asked them for their child's date of birth at the beginning of the survey, and repeated the question at the end of the survey. Participants for whom these dates did not coincide were excluded (n = 16). Moreover, to ensure that participants were not responding in a random fashion, we included additional quality control questions throughout the survey. From the 1284 remaining participants, 234 were excluded from our analysis because they failed to answer correctly 1 or more of the 8 quality control questions, and 50 were excluded owing to unanswered questions. On completing the questionnaire, participants received instructions to enter a unique code in the MTurk HIT to verify survey completion and to receive the payment. No personal information was stored. Data were stored through the password-protected SurveyGizmo username and the PAIN Group at Boston Children's Hospital protected server.
Survey
To test whether the language used in the survey was adequate and did not lead to biased responses, the survey was piloted online in 17 participants, who were then asked to comment on the language and understanding of the questions used. Changes were implemented in the survey accordingly.
The final version of the survey consisted of 35 questions (using mostly a 7-point Likert-type scale response) presented in an 11-page survey, with an average of 5.6 questions per page and no option to go back and change previous answers. The questions in the survey can be clustered into 4 distinct thematic sections. The first section inquired about basic demographics, the general health of their children, and general beliefs regarding mind-body influences on health.
The next section provides a brief definition of placebo's therapeutic benefits and underlying mechanisms (Appendix 3; available at www.jpeds.com). Parents were then asked about general acceptability regarding the use of placebo in pediatrics, and acceptable target conditions. In the third section, parents were provided with a definition of placebo, focusing on its control role in clinical trials, then asked questions regarding their attitudes toward clinical trials in general and toward the use of placebo in pediatric trials. Finally, in the last section, parents were asked about placebo-related ethical considerations: pure vs impure placebos; deception in pediatric placebo administration; and creation of placebo guidelines.
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278.e1
Parental Attitudes About Placebo Use in Children Parents attitudes on placebo (Survey for parents with children under the age of 18)
Please note that this study is meant to survey the attitudes of parents on the prescribing of placebo. If you do not have any children under the age of 18, please return this HIT.
Demographic questions
The answers to these questions will help us describe who participated in this survey: 
278.e2
This survey is mainly focused on pediatric/child care. Please note that there are no right or wrong answers, we are only interested in your opinion as a parent. 5. I have read the previous paragraph that provides a definition of the placebo effect. Yes 6. According to the explanatory paragraph, that provided a definition of the placebo effect, when does a patient experience a placebo effect? When the patient gets better not because of the treatment itself, but rather because the patient expects the treatment to work. the patient gets better not because the patients expects the treatment to work, but rather because of the treatment itself. 35. Did you answer these questions honestly and therefore they can be used in this research? Please be aware that dishonest/non truthful answers will impact negatively this study (You will be paid regardless of your answer).
Yes No
Thank you for participating in this survey. If you have any questions, or comments please don't hesitate in leaving them in the following space.
Appendix 2. Continued.
Appendix 3
A patient experiences a placebo effect when he or she gets better not because of the treatment itself, but rather because he or she expects the treatment to work. Research studies have shown that the placebo effect works through naturally occurring brain chemicals called neurotransmitters that are released when the patient expects a treatment to be beneficial. For example, a placebo effect can occur when a person uses a skin cream for pain relief. Even though the cream has no active ingredients for reducing pain, through the release of neurotransmitters in the brain the person will feel less pain. Importantly, whereas historically it was thought that placebos worked only if patients were misled to think that they were taking drugs, recent studies have shown that placebos are able to produce beneficial effects even when patients are aware that they are taking placebos. In other words, deception is not needed to achieve a therapeutic placebo response. Owing to its known beneficial effects, placebos have been used extensively in clinical research. Randomized clinical studies are specific scientific experiments designed to test the efficacy of new drugs/treatments. If there are no drugs available on the market to treat a particular condition, then the new drug will be tested or compared against a placebo; however, if there are already approved drugs to treat that condition, the new drug might be tested/compared against the already existing drug or a placebo. So in these studies, patients are randomly allocated to the new drug being tested, and are compared with either an already existing drug or a placebo. The main goal is to test the effectiveness of the new drug and its side effects. The outcome of these studies will impact pediatric care. 
